United Therapeutics
UTHR
526 hedge funds and large institutions have $10.4B invested in United Therapeutics in 2024 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 215 increasing their positions, 182 reducing their positions, and 60 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 182
6% more capital invested
Capital invested by funds: $9.85B → $10.4B (+$561M)
1.1% more ownership
Funds ownership: 95.15% → 96.25% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
4% less call options, than puts
Call options by funds: $270M | Put options by funds: $281M
7% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 60
2% less funds holding
Funds holding: 535 → 526 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$145M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$83.3M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$66.6M |
| 4 |
BlackRock
New York
|
+$61.5M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
+$59.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$294M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$86.1M |
| 3 |
O
OrbiMed
New York
|
-$84.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$82.6M |
| 5 |
Janus Henderson Group
London,
|
-$53M |
UTHR Hedge Fund Activity: Q1 2024 in Review
526 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2024, worth a combined $10.4B — up 5.7% from $9.85B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of UTHR and 56 opened new positions — a net loss of 4 holders — while 182 trimmed existing stakes and 215 added.
The largest buyer was Citadel Advisors, adding an estimated $145M. The largest seller was Fidelity Investments, cutting an estimated $294M.
- 526 institutional investors held United Therapeutics (UTHR) as of Q1 2024, down from 535 in Q4 2023.
- Funds reported $10.4B of United Therapeutics stock for Q1 2024, up 5.7% quarter-over-quarter.
- 56 funds opened new United Therapeutics positions in Q1 2024 and 60 closed out, a net change of -4 holders.
- The largest United Therapeutics buyer in Q1 2024 was Citadel Advisors, an estimated $145M added.
- The largest United Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $294M sold.
Based on aggregated 13F filings for Q1 2024.